Alzheimer's disease is a progressive neurodegenerative disease that affects millions of people worldwide, with a clinical pre-onset that often lasts for decades, well before obvious symptoms appear. A new analysis based on New Zealand's famous Dunedin Cohort Study shows that certain blood biomarkers, combined with participants' self-reported memory concerns, may indicate early signs of Alzheimer's-related changes in midlife. The research team believes that middle age may be a critical time window to promote brain health and carry out intervention.
The study used long-term follow-up data from the University of Otago's Dunedin Study, which followed the same participants born in the early 1970s for more than 50 years. The researchers focused on a protein called pTau181 and assessed its relationship with subjects' self-reported memory and thinking problems. The results showed that at the age of 45, participants with higher blood levels of pTau181 were more likely to express concerns about their memory and cognitive status.
This finding is of particular significance because people are often not formally diagnosed with dementia or Alzheimer's disease until they are 70 years old or even later. In other words, the "poor memory" of some middle-aged people may not be simply normal aging, but may be a subjective signal of the early process of the disease. At the same time, although Alzheimer's disease-related drugs have made progress in recent years, most of them currently can only slow down the progression of the disease and are difficult to restore cognitive functions lost in the late stages. Therefore, early identification of high-risk groups is regarded as a key prerequisite for improving treatment benefits.
In the past, a final diagnosis of Alzheimer's disease was often made only through an autopsy or through invasive tests such as a lumbar puncture to detect abnormal proteins in the cerebrospinal fluid. In recent years, research focus has increasingly turned to biomarkers that can be detected in the blood in the hope of identifying people who may be in the early stages of the disease in a less invasive way. Once risk groups can be identified before symptoms are apparent, there is an opportunity to take preventive measures earlier, thereby overall improving brain health and quality of life in old age.
The research team pointed out that prevention of dementia can include encouraging people to maintain regular physical activity, actively participate in social activities, and intervene as early as possible on certain modifiable risk factors, such as high blood pressure and hearing loss. Relevant research shows that the earlier preventive measures are implemented, the more obvious the effect on reducing the risk of dementia. Therefore, carrying out large-scale screening and risk profiling in middle age is expected to buy more time for later disease prevention and control.
As we age, it is common for people to feel that their memory is not as good as it used to be, but in most cases this forgetfulness is a common and benign part of aging. However, recent research suggests that some very subtle, subjective cognitive changes may appear long before clinical diagnosis and constitute the moment when the disease is "first perceived" by the individual. If such subjective reports could be combined with objective biological indicators, such as specific proteins in the blood, it would be possible to differentiate between normal aging and the pathological processes of early Alzheimer's disease.
Levels of proteins such as pTau181 are often significantly elevated in patients with Alzheimer's disease, but the point at which they accumulate before the onset of the disease is not fully understood. The findings add to evidence that some of the earliest signs of dementia may appear years before diagnosis, and that self-reported memory problems in middle-aged adults may be a warning sign of the early stages of Alzheimer's disease. Interestingly, the study found no significant association between pTau181 levels at age 45 and changes in magnetic resonance imaging (MRI) brain structure or performance on standardized cognitive tests.
For this result, the researchers proposed at least two possible explanations: One is that pTau181 begins to increase at the earliest stage of the disease, when patients already subjectively feel that their memory has deteriorated, but conventional brain imaging cannot capture structural changes. Another possibility is that elevated pTau181 levels in midlife are not directly linked to a specific risk of Alzheimer's disease, and that the protein may only have more predictive value in older age. Because the conclusion is uncertain, the research team plans to continue to follow the same group of participants to observe the dynamic relationship between biomarkers, subjective experience, and objective brain function in the coming decades.